- Home
- IMNN vs MBRX Comparison
IMNN vs MBRX Comparison
Compare IMNN & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- MBRX
- Stock Information
- Founded
- IMNN 1982
- MBRX 2015
- Country
- IMNN United States
- MBRX United States
- Employees
- IMNN N/A
- MBRX N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- IMNN Health Care
- MBRX Health Care
- Exchange
- IMNN Nasdaq
- MBRX Nasdaq
- Market Cap
- IMNN 12.1M
- MBRX 12.9M
- IPO Year
- IMNN 1985
- MBRX 2016
- Fundamental
- Price
- IMNN $0.77
- MBRX $0.34
- Analyst Decision
- IMNN Buy
- MBRX Strong Buy
- Analyst Count
- IMNN 2
- MBRX 3
- Target Price
- IMNN $14.00
- MBRX $5.33
- AVG Volume (30 Days)
- IMNN 2.3M
- MBRX 5.1M
- Earning Date
- IMNN 08-13-2025
- MBRX 08-13-2025
- Dividend Yield
- IMNN N/A
- MBRX N/A
- EPS Growth
- IMNN N/A
- MBRX N/A
- EPS
- IMNN N/A
- MBRX N/A
- Revenue
- IMNN N/A
- MBRX N/A
- Revenue This Year
- IMNN N/A
- MBRX N/A
- Revenue Next Year
- IMNN N/A
- MBRX N/A
- P/E Ratio
- IMNN N/A
- MBRX N/A
- Revenue Growth
- IMNN N/A
- MBRX N/A
- 52 Week Low
- IMNN $0.37
- MBRX $0.25
- 52 Week High
- IMNN $3.65
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- IMNN 40.86
- MBRX 30.62
- Support Level
- IMNN $0.70
- MBRX $0.29
- Resistance Level
- IMNN $0.86
- MBRX $0.36
- Average True Range (ATR)
- IMNN 0.10
- MBRX 0.05
- MACD
- IMNN -0.05
- MBRX 0.00
- Stochastic Oscillator
- IMNN 10.34
- MBRX 21.55
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.